Diagnosis and prognosis evaluation of 18FFDG PET/CT in bone marrow infiltration of lymphoma

doi:10.3760/cma.j.issn.1673-422X.2016.05.020

Abstract

Abstract: 18Ffluorodeoxyglucose positron emission tomography/computed tomography (18FFDG PET/CT) and bone marrow biopsy (BMB) have high consistency in the detection of lymphoma bone marrow infiltration (BMI). 18FFDG PET/CT has a high sensitivity to Hodgkin lymphoma (HL) and aggressive nonHodgkin lymphoma (NHL) BMI, while the sensitivity of indolent NHL is low. Since 18FFDG PET/CT may appears false positive or false negative, so it can not replace the conventional BMB. We can carry out a BMB under the guidance of 18FFDG PET/CT, which can greatly improve the detection rate of BMI.

Key words: Lymphoma, Bone marrow, Biopsy, Fluorodeoxyglucose F18, Tomography, spiral computed;, Prognosis

Yue Jin, Su Liping. Diagnosis and prognosis evaluation of 18FFDG PET/CT in bone marrow infiltration of lymphoma[J]. Journal of International Oncology, 2016, 43(5): 395-397.

References

［1］ Berthet L, Cochet A, Kanoun S, et al. In newly diagnosed diffuse large Bcell lymphoma, determination of bone marrow involvement with 18FFDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy［J］. J Nucl Med, 2013, 54(8): 1244-1250. DOI: 10.2967/jnumed.112.114710. ［2］ CortésRomera M, SabatéLlobera A, MercadalVilchez S, et al. Bone marrow evaluation in initial staging of lymphoma: 18FFDG PET/CT versus bone marrow biopsy［J］. Clin Nucl Med, 2014, 39(1): e46-e52. DOI: 10.1097/RLU.0b013e31828e9504. ［3］ ChenLiang TH, MartinSantos T, Jerez A, et al. The role of bone marrow biopsy and FDGPET/CT in identifying bone marrow infiltration in the initial diagnosis of high grade nonHodgkin Bcell lymphoma and Hodgkin lymphoma. Accuracy in a multicenter series of 372 patients［J］. Am J Hematol, 2015, 90(8): 686-690. DOI: 10.1002/ajh.24044. ［4］ etin G, krkolu MA, zkan T, et al. Can positron emission tomography and computed tomography be a substitute for bone marrow biopsy in detection of bone marrow involvement in patients with Hodgkin′s or nonhodgkin′s lymphoma?［J］. Turk J Hematol, 2015, 32(3): 213-219. ［5］ Hong J, Lee Y, Park Y, et al. Role of FDGPET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large Bcell lymphoma［J］. Ann Hematol, 2012, 91(5): 687-695. DOI: 10.1007/s0027701113536. ［6］ Lee Y, Hwang KH, Hong J, et al. Usefulness of (18)FFDG PET/CT for the evaluation of bone marrow involvement in patients with HighGrade NonHodgkin′s lymphoma［J］. Nucl Med Mol Imaging, 2012, 46(4): 269-277. DOI: 10.1007/s1313901201539. ［7］ Pakos EE, Fotopoulos AD, Ioannidis JP. 18FFDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a metaanalysis［J］. J Nucl Med, 2005, 46(6): 958-963. ［8］ Chen YK, Yeh CL, Tsui CC, et al. F18 FDG PET for evaluation of bone marrow involvement in nonHodgkin lymphoma: a metaanalysis［J］. Clin Nucl Med, 2011, 36(7): 553-559. DOI: 10.1097/RLU.0b013e318217aeff. ［9］ Mittal BR, Manohar K, Malhotra P, et al. Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging?［J］. Leuk Lymphoma, 2011, 52(11): 2111-2116. DOI: 10.3109/10428194.2011.593273. ［10］ Cheng G, Chen W, Chamroonrat W, et al. Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients［J］. Eur J Nucl Med Mol Imaging, 2011, 38(8): 1469-1476. DOI: 10.1007/s002590111815z. ［11］ Adams HJ, Kwee TC, Fijnheer R, et al. Bone marrow F18fluoro2deoxyDglucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large Bcell lymphoma［J］. Am J Hematol, 2014, 89(7): 726-731. DOI: 10.1002/ajh.23730. ［12］Kim TM, Paeng JC, Chun IK, et al. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma［J］. Cancer, 2013, 119(6): 1195-1202. DOI: 10.1002/cncr.27855. ［13］Khan AB, Barrington SF, Mikhaeel NG, et al. PETCT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement［J］. Blood, 2013, 122(1): 61-67. DOI: 10.1182/blood201212473389. ［14］Zhou Z, Chen C, Li X, et al. Evaluation of bone marrow involvement in extranodal NK/T cell lymphoma by FDGPET/CT［J］. Ann Hematol, 2015, 94(6): 963-967. DOI: 10.1007/s0027701422894.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[4]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[5]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[6]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[7]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[8]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[9]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[10]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[11]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[12]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[13]	Huang Zhen, Chen Yongshun. Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2024, 51(1): 59-64.
[14]	Wang Xiao, Li Ying, Luo Yujie, Jin Shu. Study on the prognostic value of serological indicators for nasopharyngeal carcinoma based on nomogram model [J]. Journal of International Oncology, 2023, 50(8): 463-469.
[15]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474.